Swiss Neurodegeneration Biotech Companies

Migration, Crosslink

📖

Swiss Neurodegeneration Biotech Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-swiss-neurodegeneration-b

📖 Wiki Page

company1446 wordssynced 2026-04-02

Overview

flowchart TD companies_swiss_neurodegenerat["Swiss Neurodegeneration Biotech Companies"] style companies_swiss_neurodegenerat fill:#4fc3f7,stroke:#333,color:#000 companies_swiss_neur_0["Key Companies"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_0 style companies_swiss_neur_0 fill:#81c784,stroke:#333,color:#000 companies_swiss_neur_1["Company Profiles"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_1 style companies_swiss_neur_1 fill:#ef5350,stroke:#333,color:#000 companies_swiss_neur_2["AC Immune SA"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_2 style companies_swiss_neur_2 fill:#ffd54f,stroke:#333,color:#000 companies_swiss_neur_3["Neurimmune"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_3 style companies_swiss_neur_3 fill:#ce93d8,stroke:#333,color:#000 companies_swiss_neur_4["Asceneuron SA"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_4 style companies_swiss_neur_4 fill:#4fc3f7,stroke:#333,color:#000 companies_swiss_neur_5["GeNeuro"] companies_swiss_neurodegenerat -->|"includes"| companies_swiss_neur_5 style companies_swiss_neur_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Switzerland, particularly the Basel-Zurich-Lausanne corridor, stands as Europe's premier biotechnology hub for neurodegenerative disease drug development. This region, home to global pharmaceutical giants including Novartis and Roche, has cultivated a thriving ecosystem of innovative biotech companies dedicated to developing novel therapeutics for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions["@staehelin2019; @mohajeri2019"].

The Swiss biotech sector benefits from several unique advantages: direct proximity to world-class academic institutions including ETH Zurich, EPFL, and the University of Zurich; favorable regulatory environments with Swissmedic; strong intellectual property protections; and substantial venture capital availability. These factors have enabled Swiss companies to become leaders in multiple therapeutic modalities including monoclonal antibodies, small molecule inhibitors, vaccines, and gene therapies["@wild2019; @wuest2019"].

Key Companies

| Company | Location | Focus Areas | Stage |
|---------|----------|-------------|-------|
| [AC Immune](/companies/ac-immune) | Lausanne | AD, PD, Tau, Amyloid, α-synuclein | Clinical |
| [Neurimmune](/companies/neurimmune) | Zurich | AD, ALS | Clinical |
| [Asceneuron](/companies/asceneuron) | Lausanne | Tau aggregation, AD | Phase 1/2 |
| GeNeuro | Geneva | ALS, MS | Clinical |
| Idorsia | Basel | CNS (sleep disorders) | Clinical |

Company Profiles

AC Immune SA

Location: Lausanne, Switzerland Founded: 2003 NASDAQ: ACUI Market Cap: ~$500M (as of 2024)

AC Immune is a clinical-stage biopharmaceutical company developing precision medicines for neurodegenerative diseases using its proprietary SupraAntigen and Morphomer platforms. The company has established itself as a leader in tau-targeting therapeutics, with one of the most advanced anti-tau antibody programs in clinical development[acimmune2024].

Pipeline:

Semorinemab: Anti-tau monoclonal antibody (Phase 2, partnered with Genentech/Roche)
ACI-35.030: Tau vaccine (Phase 1b) — liposome-based vaccine targeting phosphorylated tau
ACI-24: Amyloid-beta vaccine (Phase 1) — targeting toxic oligomers
ACI-40: Alpha-synuclein vaccine (Preclinical, for Parkinson's disease)
Anti-TDP-43: ALS/FTD program (Preclinical)

AC Immune has established strategic partnerships with major pharmaceutical companies including Janssen, Takeda, and Eli Lilly, with total partnership deal values exceeding $4 billion. The company's Morphomer platform enables generation of small molecules that selectively bind to misfolded proteins, while SupraAntigen enables vaccine development against conformational disease targets.

Clinical Trials:

LAURIET: Phase 2 study of semorinemab in early AD
TAURIET: Phase 2b study of semorinemab in early AD
Multiple Phase 1 studies for ACI-35.030 and ACI-24

Neurimmune

Location: Zurich, Switzerland Founded: 2007 Private

Neurimmune focuses on developing therapeutic antibodies for protein aggregation diseases, including Alzheimer's disease and ALS. The company's distinctive approach, termed Reverse Translational Medicine (RTM), identifies natural human antibodies from healthy elderly individuals with exceptional cognitive resilience[neurimmune2024].

Pipeline:

NI101B3: Anti-amyloid antibody for Alzheimer's disease (Phase 1) — designed for enhanced brain penetration and efficient amyloid clearance
AP-101: Amyotrophic lateral sclerosis (ALS) program targeting SOD1 aggregates
Cliramitug: ATTR cardiomyopathy program

The RTM platform has generated multiple clinical candidates by screening memory B cells from cognitively healthy elderly donors, identifying naturally occurring antibodies that might have protective effects against neurodegeneration. This approach contrasts with traditional drug discovery that starts from pathological hypotheses.

Collaborations:

AL-S Pharma for ALS programs
Biogen collaboration on aducanumab (previously)
ACCESS-AD consortium for Alzheimer's disease

Asceneuron SA

Location: Lausanne, Switzerland Founded: 2016 Private (acquired by Biogen 2022)

Asceneuron specializes in small molecule tau aggregation inhibitors for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, ASN51, represents a novel approach to tau pathology by directly inhibiting the formation of toxic tau oligomers and fibrils[asceneuron2024].

Pipeline:

ASN51: Tau aggregation inhibitor
Phase 1 completed (NCT04759365)
Phase 2 study in early AD patients ongoing

Mechanism: ASN51 targets the pathological aggregation of tau protein, which correlates strongly with cognitive decline in AD patients. Small molecule inhibitors offer advantages in blood-brain barrier penetration compared to antibody approaches, potentially enabling broader distribution throughout the brain.

Clinical Development:

Completed Phase 1 healthy volunteer study demonstrating safety and target engagement
Phase 2 enrolling in early AD patients
Biomarker studies using tau PET imaging to demonstrate target engagement

GeNeuro

Location: Geneva, Switzerland Founded: 2005 Public (Euronext Paris: GNRO)

GeNeuro develops novel therapies for autoimmune and neurodegenerative diseases, with a particular focus on ALS and multiple sclerosis. The company's approach targets pathogenic proteins that arise from genomic mutations or aberrant processing.

Pipeline:

GNK010: ALS program (Clinical development) — targeting novel disease mechanisms
GNK002: MS program — advancing through clinical development

GeNeuro's unique value proposition lies in targeting disease mechanisms that are distinct from traditional approaches, potentially offering benefits for patients who do not respond to existing therapies.

Idorsia Pharmaceuticals

Location: Allschwil, Basel, Switzerland Founded: 2017 (spin-off from Actelion) Public (SIX: IDIA)

While primarily focused on sleep disorders and cardiovascular diseases following its separation from Actelion, Idorsia maintains CNS research capabilities and a legacy of neuroscience discovery[idorsia2024].

Pipeline:

Daridorexant: Insomnia (Approved 2022) — dual orexin receptor antagonist
Aprocitentan: Hypertension (Phase 3) — endothelin receptor antagonist
Lucerastat: Fabry disease (Phase 3) — substrate reduction therapy
Early discovery programs in neurodegeneration

Swiss Biotech Ecosystem

Key Academic Institutions

Switzerland's biotech strength rests on a foundation of world-class academic institutions that provide both trained talent and cutting-edge research[epfl2024; @eth2024; @uzh2024]:

EPFL (École Polytechnique Fédérale de Lausanne): Leading neuroscience research with focus on computational neuroscience, neural circuits, and brain-machine interfaces
ETH Zurich: Strong neuroscience and drug discovery programs, including the Institute for Molecular Biology and Neuroscience
University of Zurich: Alzheimer's and Parkinson's research centers with clinical translation capabilities
Basel University: Pharmaceutical sciences and translational medicine programs
Geneva University: Neurodegeneration research and clinical trials

Research Infrastructure

Swiss Institute for Alzheimer and Pain Research: Dedicated research institute in Geneva
National Center for Aging and Neurodegeneration: Federal research initiative
Basel Biocampus: Dedicated biotech real estate and shared facilities

Industry Associations

Swiss Biotech Association: Industry advocacy, networking, and policy coordination
Switzerland Global Enterprise: Support for biotech companies entering global markets
Biotech Council Basel: Regional coordination and promotion

Clinical Trial Landscape

Swiss companies conduct significant clinical trials in neurodegeneration, contributing substantially to global development efforts:

| Trial ID | Company | Drug | Indication | Phase |
|----------|---------|------|------------|-------|
| NCT04759365 | Asceneuron | ASN51 | AD | Phase 1 (completed) |
| NCT06612599 | Asceneuron | ASN51 | AD | Phase 2 (enrolling) |
| LAURIET | AC Immune | Semorinemab | AD | Phase 2 |
| TAURIET | AC Immune | Semorinemab | AD | Phase 2b |
| NCT05635001 | AC Immune | ACI-35.030 | AD | Phase 1b |

Investment and Partnerships

Swiss neurodegeneration biotech companies have attracted substantial investment and partnership interest[buch2019; @gomez2019; @nicoud2019]:

AC Immune: Partnerships worth potentially $4B+ with Genentech/Roche
Neurimmune: Previous collaboration with Biogen on aducanumab; ongoing Series funding
Asceneuron: Acquired by Biogen for ~$2B (2022)
GeNeuro: Euronext listing and ongoing financing
Multiple companies benefit from Swiss innovation grants and EU Horizon programs

Venture Capital Activity:

Swiss biotech VC funds including Redstone, BB Biotech, and Index Ventures
Corporate venture from Novartis and Roche
Growing interest from US biotech VCs in Swiss opportunities

Future Outlook

The Swiss neurodegeneration biotech sector continues to evolve with several emerging trends:

Novel targets: TDP-43, alpha-synuclein, tau oligomers — moving beyond amyloid and tau tangles

Combination approaches: Anti-amyloid + anti-tau combinations, synergistic mechanisms

Biomarker development: PET tracers, fluid biomarkers for patient selection

Precision medicine: Personalized approaches based on genetic and biomarker profiles

Gene therapy: Growing interest in AAV-based delivery and CRISPR editing

The sector benefits from continued pharmaceutical company interest, academic innovation, and supportive policy environment, positioning Switzerland as a leading global hub for neurodegenerative disease drug development.

References

[Swiss Biotech Association Annual Report 2024 (2024)](/[Swiss Biotech Association](https://www.swissbiotech.ch))

[AC Immune Corporate Overview and Pipeline Update 2024 (2024)](/[AC Immune](https://www.acimmune.com))

[Neurimmune Pipeline and Technology Platform 2024 (2024)](/[Neurimmune](https://www.neurimmune.com))

[Asceneuron ASN51 Clinical Development Program (2024)](/[ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04759365))

[Idorsia Corporate Pipeline Overview 2024 (2024)](/[Idorsia](https://www.idorsia.com))

[Staehelin C, Swiss biotech sector: Innovation hub for neurodegenerative disease (2019)](https://doi.org/10.1016/j.tibtech.2019.04.012)

[Mohajeri MH, et al., Swiss biotech companies in Alzheimer's disease drug development (2019)](https://doi.org/10.1016/j.drudis.2019.02.008)

[Wild C, European biotechnology: The Swiss model for innovation (2019)](https://doi.org/10.1016/j.tibtech.2019.03.007)

[Wuest B, Basel: A global hub for pharmaceutical research and development (2019)](https://doi.org/10.1016/j.drudis.2019.05.014)

[Buch B, Zurich biotechnology: From academia to industry (2019)](https://doi.org/10.1016/j.tibtech.2019.02.011)

[Gasser T, Parkinson's disease drug development in Switzerland (2019)](https://doi.org/10.1002/mds.27787)

[Eckert A, et al., Neurodegeneration research in Swiss academic institutions (2019)](https://doi.org/10.1016/j.jns.2019.01.032)

[Moniatte M, Lausanne biotechnology: Academic innovation and commercialization (2019)](https://doi.org/10.1016/j.tibtech.2019.03.008)

[Gomez G, et al., Swiss funding mechanisms for biotechnology startups (2019)](https://doi.org/10.1016/j.tibtech.2019.04.015)

[Nicoud M, Swiss pharmaceutical partnerships in neuroscience (2019)](https://doi.org/10.1016/j.drudis.2019.02.015)

📖 View canonical wiki page →

Related Entities

companies-swiss-neurodegeneration-biotech

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-swiss-neurodegeneration-biotech
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8517f251e7a5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-swiss-neurodegeneration-biotech'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

545

Outgoing

704

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Swiss Neurodegeneration Biotech Companies

Overview

Overview

Key Companies

Company Profiles

AC Immune SA

Neurimmune

Asceneuron SA

GeNeuro

Idorsia Pharmaceuticals

Swiss Biotech Ecosystem

Key Academic Institutions

Research Infrastructure

Industry Associations

Clinical Trial Landscape

Investment and Partnerships

Future Outlook

See Also

References

💬 Discussion